Literature DB >> 11453866

Long-term follow-up of idiopathic central serous chorioretinopathy without laser.

D Bujarborua1.   

Abstract

PURPOSE: The purpose of this study was to observe the varied types of manifestations in the fundus of patients with idiopathic central serous chorioretinopathy (ICSC) without laser treatment and also to assess the ultimate visual outcome in such cases in a long-term follow-up ranging from 7 to 23 years.
METHODS: This study is confined to 5 selected cases of ICSC which fairly represent the different types of late stage manifestations of the disease in the fundus. Case records from our hospital, as well as available records of previous treatment elsewhere were reviewed. A complete ophthalmological examination, routine laboratory investigations and fluorescein fundus angiography (FFA) were repeated in each case on the day of final evaluation.
RESULTS: Pigmentary disturbances in the macular area resembling to some extent age-related macular degeneration (AMD), extensive retinal pigment epithelial (RPE) atrophy and macular haemorrhage have been observed in the fundus of the reviewed cases.
CONCLUSIONS: ICSC runs an unpredictable course and there are no definitive clinical clues to predict its ultimate outcome. Recurrence of the condition is a possibility for a considerable period of time.

Entities:  

Mesh:

Year:  2001        PMID: 11453866     DOI: 10.1034/j.1600-0420.2001.079004417.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  29 in total

1.  Transpupillary thermotherapy for chronic central serous chorioretinopathy.

Authors:  Nazimul Hussain; Rohit Khanna; Anjli Hussain; Taraprasad Das
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

2.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

3.  Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome.

Authors:  N K Yadav; C Jayadev; A Mohan; P Vijayan; R Battu; S Dabir; B Shetty; R Shetty
Journal:  Eye (Lond)       Date:  2015-01-23       Impact factor: 3.775

4.  Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.

Authors:  Young Gun Park; Seungbum Kang; Minhee Kim; Nari Yoo; Young Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

Review 5.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

6.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

7.  Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Authors:  Vladimir Sheptulin; Konstantine Purtskhvanidze; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117

Review 8.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

9.  Polypoidal choroidal vasculopathy and history of central serous chorioretinopathy.

Authors:  T Toyama; K Ohtomo; Y Noda; T Ueta
Journal:  Eye (Lond)       Date:  2014-06-13       Impact factor: 3.775

10.  Smokestack leak in central serous chorioretinopathy.

Authors:  Dhiren Bujarborua; Pran N Nagpal; Manab Deka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.